|
Treating Behavioral Disturbances in Individuals with Dementia Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Treating Behavioral Disturbances in Individuals with Dementia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Treating Behavioral Disturbances in Individuals with Dementia Clinical research trials and Treating Behavioral Disturbances in Individuals with Dementia healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Treating Behavioral Disturbances in Individuals with Dementia. Treating Behavioral Disturbances in Individuals with Dementia Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Treating Behavioral Disturbances in Individuals with Dementia clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Treating Behavioral Disturbances in Individuals with Dementia condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treating Behavioral Disturbances in Individuals with Dementia  Treating Behavioral Disturbances in Individuals with Dementia
Treating Behavioral Disturbances in Individuals with Dementia
For Condition: Alzheimer Disease,Dementia
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to compare the safety and effectiveness of the drugs citalopram and risperidone for the treatment of behavioral and psychotic disturbances associated with dementia.
Details: Dementia-related behavioral disturbances have been associated with excess disability, increased caregiver burden, and premature institutionalization. Pharmacotherapy is often necessary to treat these disturbances. This study will use citalopram and risperidone to treat people with dementia-related behavior problems. Participants in this study will begin a psychotropic medication washout period for up to 3 days at study start. Participants will then be randomly assigned to receive either citalopram or risperidone for up to 12 weeks. Limited doses of the sedative lorazepam may be administered as needed throughout the study. During the first 2 weeks of the study, participants will be admitted to a hospital to have their dementia-related behavioral disturbances stabilized. Following hospital discharge, participants will move to a long-term care facility or a residential home and will continue medication treatment for up to 10 weeks. Side effects and improvements in behavioral status will be assessed every week until Week 6 and every 2 weeks thereafter. Experimental laboratory measures will be collected at study start, Week 1, Week 2, and every 2 weeks thereafter until Week 12. Upon study completion, patients may continue to receive citalopram or risperidone under the supervision of their current physicians. Three months after study completion, participants may be contacted for a follow-up report of their psychiatric and medical status.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of Alzheimer’s type dementia and/or meet criteria for probable or possible Alzheimer’s disease - Inpatient admittance to Western Psychiatric Institute and Clinic - Written informed consent from participant's legally authorized representative with the participant’s assent - Psychosis or behavioral problems severe enough to be a danger to the participant’s health, well-being, or safety - Score of 3 to 6 (moderate to severe) on at least one of the Neurobehavioral Rating Scale (NBRS) agitation or psychosis items - Ability to participate in study evaluation and ingest oral medication Exclusion Criteria: - Diagnosis of an unstable medical illness within the last 12 months - Kidney or liver dysfunction - Diagnosis of delirium, substance-induced persisting dementia, or vascular dementia - Score of 12 or higher on the Cornell Scale for Depression in Dementia, and a score greater than 3 on the depression item of the NBRS - Diagnosis of Parkinson’s disease or any neurological illness which may affect cognitive function - History of schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, or bipolar affective disorder - Alcohol or substance abuse or dependence - Receiving monoamine oxidase inhibitors within 15 days of study - Display behaviors which could endanger the participant’s life or the lives of others - Received fluoxetine within 4 weeks of screening
Total Enrollment: 103
Location and Contact Information:
Overall Study Official:
BrucePollock, Principal Investigator, University of Pittsburgh
University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Mary Hall 412-246-6274
Additional Information:
Study ID Numbers: MH59666; 5 R01-MH59666
Study Start Date: March 2000
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073658
Other Alzheimer Disease Studies:
1. Alzheimer's Disease Prevention Trial
2. Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
3. Valproate in Dementia (VALID)
4. Healthy Aging and Memory Study
5. Treating Behavioral Disturbances in Individuals with Dementia
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Treating Behavioral Disturbances in Individuals with Dementia
|
|
|
|
|
|
|
|
